Sertraline in coexisting major depression and diabetes mellitus

Paul J. Goodnick, Adarsh Kumar, Joseph H. Henry, Virginia M V Buki, Ronald B. Goldberg

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

As many as 25 percent of patients with diabetes mellitus may also have depressive symptoms. Tricyclic antidepressants (TCAs) may produce increased appetite end weight gain with adverse consequences for diabetes. The selective serotonin reuptake inhibitors (SSRIs), however, may improve fasting blood sugar in laboratory studies. In an initial application, sertraline was administered at a dose of 50 mg/day in a 10-week open study to 28 non- insulin-dependent diabetes mellitus (NIDDM) patients with DSM-III-R major depression after a 2-week single-blind placebo washout period with a minimum 17-item Hamilton Rating Scale for Depression (HAM-D) score of 18. The patient group included 16 males and 12 females with a mean age of 54.2 ±8.8 years. Results indicated (1) significant improvement in mean HAM-D (22.5 ± 3.4 to 4.9 ± 5.9, p<.001) and in mean Beck Depression inventory (BDI) scores (21.9 ± 10.5 to 12.7 ± 8.3, p<.001); (2) fall in platelet serotonin (5-HT) content (79.7 ± 22.5 to 13.6 ± 12.7 ng/108 platelets, p<.001); (3) correlation of baseline platelet 5-HT content with response to sertraline by BDI scores (r=0.51, p<.05); (4) improved dietary compliance for those with baseline value below 70 percent (59.7% to 69.1%, p<.005); and (5) 13 of 17 patients with baseline glycosylated hemoglobin A (HbA(1c)) levels greater than 8.0, showed a reduction (p=.018). Sertraline may be an effective antidepressant in patients with diabetes mellitus end response may be predictable by higher baseline platelet 5-HT content, with the potential to improve dietary compliance and reduce HbA(1c) measures. As with all open studies, replication is essential.

Original languageEnglish
Pages (from-to)261-264
Number of pages4
JournalPsychopharmacology Bulletin
Volume33
Issue number2
StatePublished - Jul 24 1997

Fingerprint

Sertraline
Diabetes Mellitus
Depression
Serotonin
Blood Platelets
Equipment and Supplies
Tricyclic Antidepressive Agents
Glycosylated Hemoglobin A
Serotonin Uptake Inhibitors
Appetite
Diagnostic and Statistical Manual of Mental Disorders
Type 2 Diabetes Mellitus
Antidepressive Agents
Weight Gain
Blood Glucose
Fasting
Placebos

Keywords

  • Depression
  • Diabetes mellitus
  • Prediction
  • Serotonin
  • Sertraline

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Sertraline in coexisting major depression and diabetes mellitus. / Goodnick, Paul J.; Kumar, Adarsh; Henry, Joseph H.; Buki, Virginia M V; Goldberg, Ronald B.

In: Psychopharmacology Bulletin, Vol. 33, No. 2, 24.07.1997, p. 261-264.

Research output: Contribution to journalArticle

Goodnick, Paul J. ; Kumar, Adarsh ; Henry, Joseph H. ; Buki, Virginia M V ; Goldberg, Ronald B. / Sertraline in coexisting major depression and diabetes mellitus. In: Psychopharmacology Bulletin. 1997 ; Vol. 33, No. 2. pp. 261-264.
@article{9d454bcd517c44929c56e5a4ca950f89,
title = "Sertraline in coexisting major depression and diabetes mellitus",
abstract = "As many as 25 percent of patients with diabetes mellitus may also have depressive symptoms. Tricyclic antidepressants (TCAs) may produce increased appetite end weight gain with adverse consequences for diabetes. The selective serotonin reuptake inhibitors (SSRIs), however, may improve fasting blood sugar in laboratory studies. In an initial application, sertraline was administered at a dose of 50 mg/day in a 10-week open study to 28 non- insulin-dependent diabetes mellitus (NIDDM) patients with DSM-III-R major depression after a 2-week single-blind placebo washout period with a minimum 17-item Hamilton Rating Scale for Depression (HAM-D) score of 18. The patient group included 16 males and 12 females with a mean age of 54.2 ±8.8 years. Results indicated (1) significant improvement in mean HAM-D (22.5 ± 3.4 to 4.9 ± 5.9, p<.001) and in mean Beck Depression inventory (BDI) scores (21.9 ± 10.5 to 12.7 ± 8.3, p<.001); (2) fall in platelet serotonin (5-HT) content (79.7 ± 22.5 to 13.6 ± 12.7 ng/108 platelets, p<.001); (3) correlation of baseline platelet 5-HT content with response to sertraline by BDI scores (r=0.51, p<.05); (4) improved dietary compliance for those with baseline value below 70 percent (59.7{\%} to 69.1{\%}, p<.005); and (5) 13 of 17 patients with baseline glycosylated hemoglobin A (HbA(1c)) levels greater than 8.0, showed a reduction (p=.018). Sertraline may be an effective antidepressant in patients with diabetes mellitus end response may be predictable by higher baseline platelet 5-HT content, with the potential to improve dietary compliance and reduce HbA(1c) measures. As with all open studies, replication is essential.",
keywords = "Depression, Diabetes mellitus, Prediction, Serotonin, Sertraline",
author = "Goodnick, {Paul J.} and Adarsh Kumar and Henry, {Joseph H.} and Buki, {Virginia M V} and Goldberg, {Ronald B.}",
year = "1997",
month = "7",
day = "24",
language = "English",
volume = "33",
pages = "261--264",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "2",

}

TY - JOUR

T1 - Sertraline in coexisting major depression and diabetes mellitus

AU - Goodnick, Paul J.

AU - Kumar, Adarsh

AU - Henry, Joseph H.

AU - Buki, Virginia M V

AU - Goldberg, Ronald B.

PY - 1997/7/24

Y1 - 1997/7/24

N2 - As many as 25 percent of patients with diabetes mellitus may also have depressive symptoms. Tricyclic antidepressants (TCAs) may produce increased appetite end weight gain with adverse consequences for diabetes. The selective serotonin reuptake inhibitors (SSRIs), however, may improve fasting blood sugar in laboratory studies. In an initial application, sertraline was administered at a dose of 50 mg/day in a 10-week open study to 28 non- insulin-dependent diabetes mellitus (NIDDM) patients with DSM-III-R major depression after a 2-week single-blind placebo washout period with a minimum 17-item Hamilton Rating Scale for Depression (HAM-D) score of 18. The patient group included 16 males and 12 females with a mean age of 54.2 ±8.8 years. Results indicated (1) significant improvement in mean HAM-D (22.5 ± 3.4 to 4.9 ± 5.9, p<.001) and in mean Beck Depression inventory (BDI) scores (21.9 ± 10.5 to 12.7 ± 8.3, p<.001); (2) fall in platelet serotonin (5-HT) content (79.7 ± 22.5 to 13.6 ± 12.7 ng/108 platelets, p<.001); (3) correlation of baseline platelet 5-HT content with response to sertraline by BDI scores (r=0.51, p<.05); (4) improved dietary compliance for those with baseline value below 70 percent (59.7% to 69.1%, p<.005); and (5) 13 of 17 patients with baseline glycosylated hemoglobin A (HbA(1c)) levels greater than 8.0, showed a reduction (p=.018). Sertraline may be an effective antidepressant in patients with diabetes mellitus end response may be predictable by higher baseline platelet 5-HT content, with the potential to improve dietary compliance and reduce HbA(1c) measures. As with all open studies, replication is essential.

AB - As many as 25 percent of patients with diabetes mellitus may also have depressive symptoms. Tricyclic antidepressants (TCAs) may produce increased appetite end weight gain with adverse consequences for diabetes. The selective serotonin reuptake inhibitors (SSRIs), however, may improve fasting blood sugar in laboratory studies. In an initial application, sertraline was administered at a dose of 50 mg/day in a 10-week open study to 28 non- insulin-dependent diabetes mellitus (NIDDM) patients with DSM-III-R major depression after a 2-week single-blind placebo washout period with a minimum 17-item Hamilton Rating Scale for Depression (HAM-D) score of 18. The patient group included 16 males and 12 females with a mean age of 54.2 ±8.8 years. Results indicated (1) significant improvement in mean HAM-D (22.5 ± 3.4 to 4.9 ± 5.9, p<.001) and in mean Beck Depression inventory (BDI) scores (21.9 ± 10.5 to 12.7 ± 8.3, p<.001); (2) fall in platelet serotonin (5-HT) content (79.7 ± 22.5 to 13.6 ± 12.7 ng/108 platelets, p<.001); (3) correlation of baseline platelet 5-HT content with response to sertraline by BDI scores (r=0.51, p<.05); (4) improved dietary compliance for those with baseline value below 70 percent (59.7% to 69.1%, p<.005); and (5) 13 of 17 patients with baseline glycosylated hemoglobin A (HbA(1c)) levels greater than 8.0, showed a reduction (p=.018). Sertraline may be an effective antidepressant in patients with diabetes mellitus end response may be predictable by higher baseline platelet 5-HT content, with the potential to improve dietary compliance and reduce HbA(1c) measures. As with all open studies, replication is essential.

KW - Depression

KW - Diabetes mellitus

KW - Prediction

KW - Serotonin

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=0030788606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030788606&partnerID=8YFLogxK

M3 - Article

C2 - 9230640

AN - SCOPUS:0030788606

VL - 33

SP - 261

EP - 264

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 2

ER -